TIDMAGL
RNS Number : 8379P
Angle PLC
11 June 2015
For immediate release 11 June 2015
ANGLE plc
("ANGLE" or "the Company")
PARSORTIX SYSTEM HARVESTS CTCS IN 100% OF PROSTATE CANCER
PATIENTS
Barts study demonstrates Parsortix harvested cells are
clinically relevant in prostate cancer
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is delighted to announce new results from its key opinion
leader, Barts Cancer Institute (BCI), investigating the clinical
use of the Parsortix system in prostate cancer patients.
Prostate cancer is the second most common cancer in men and the
fourth most common overall. More than 1.1 million cases of prostate
cancer were recorded in 2012, accounting for around 8 per cent of
all new cancer cases and 15 per cent in men (Source: World Cancer
Research Fund International).
BCI, part of Queen Mary University of London's School of
Medicine & Dentistry, is home to world-class clinical,
translational and basic scientific research and is one of the top
five cancer research centres in the UK. BCI is publishing the
results of the most recent phase of its work at a symposium hosted
by the British Association for Cancer Research and Cancer Research
UK on "Evolution and Intratumoural Heterogeneity" being held today
at the Royal Society of Medicine, London. A copy of the poster
publication is available on the ANGLE website here
http://www.angleplc.com/the-parsortix-system/download-files/.
The results published today come from an initial study of 52
prostate cancer patient samples of which 44 were with metastatic
and 8 were with localised diseases.
Using the Parsortix system, BCI researchers were able to
successfully harvest CTCs from 100% of the patients. The Parsortix
system harvested a range of different circulating cells comprising
not only CK+ cells (epithelial cells), which can be captured using
traditional antibody-based capture systems, but also CK- Vimentin+
cells (mesenchymal cells). The latter are known to play a crucial
role in the process of cancer metastasis, which leads to secondary
cancers - the most common cause of death from cancer - and cannot
be captured using traditional antibody-based systems.
Although it has limitations in detecting cancer, for patients
known to have prostate cancer, prostate-specific antigen (PSA)
levels in the blood are widely used as a clinical marker to assess
cancer progression. The number of mesenchymal cells harvested by
the Parsortix system correlated much more strongly with PSA levels
than the epithelial cells. BCI is the first group to demonstrate
the correlation between mesenchymal cells and PSA levels in
prostate cancer patients. This breakthrough research suggests that
the cells harvested by the Parsortix system are clinically relevant
and offers the potential for the Parsortix system to be used to
provide a repeatable, non-invasive liquid biopsy for prostate
cancer patients.
BCI researchers are continuing to expand the work undertaken
with more patient numbers and with ongoing follow-up of the
patients studied so far. In addition they are investigating:
-- the viability of CTCs after their harvest from the Parsortix
system and the potential to culture them. Culturing CTCs could
provide a way to test the likely effectiveness of a proposed
treatment before administering the patient with a given drug
-- the molecular biomarkers in the CTCs harvested by the
Parsortix system to predict prostate cancer patient outcome and
response to therapies.
Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer
Institute, commented:
"This work has confirmed the ability of the Parsortix system to
harvest clinically relevant mesenchymal cells and that these cells
correlate with the patient PSA level, the current gold standard for
assessing whether the patient's prostate cancer is progressing. We
are looking forward to the next stage of the work investigating
molecular biomarkers on the harvested cells and hope that this may
help guide effective treatment for prostate cancer patients in the
future."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The prospect of deployment of our repeatable, non-invasive
liquid biopsy in the treatment of prostate cancer patients in
therapy selection and remission monitoring is exciting. These
findings are encouraging and we look forward to further
developments as soon as possible."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles,
Jane Glover 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, China and Australia and three
extensive families of patents are being progressed worldwide. The
system is based on a microfluidic device that captures cells based
on a combination of their size and compressibility. The Parsortix
system is established with strong positive evaluations from leading
cancer research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These key opinion leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
About Barts Cancer Institute http://www.bci.qmul.ac.uk/about-us
Barts Cancer Institute is part of the Barts Cancer Research UK
Centre of Excellence and one of the top five cancer research
centres in the UK.
Barts Cancer Institute, within the Barts and the London School
of Medicine and Dentistry, was recently placed in the top ten
medical schools in the UK and world-wide.
Located in the Centre of London in Charterhouse Square - 1 of 3
Queen Mary University of London campuses - over 40 research groups
across Barts Cancer Institute's six specialist Centres create
world-class outputs in research, clinical trials and teaching.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMGMVLGRGKZM
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024